Neuvotion, an early-stage medical device company specialising in AI-driven neuromodulation technologies, has received FDA 510(k) clearance for its first product, NeuStim™.
This non-invasive, wearable device provides precise electrical muscle stimulation without the need for surgery. It is designed to support hand movement recovery in individuals affected by stroke or spinal cord injuries.
NeuStim™ features an advanced touch-screen interface that allows clinicians to identify stimulation targets quickly.
The device also enables users to set up and save stimulation profiles through an intuitive graphical user interface on a lightweight mobile platform.
With a foundation built on two decades of scientific research, Neuvotion focuses on developing innovative technologies for neurorehabilitation, brain-computer interface (BCI), and physical therapy applications.
The company plans to introduce NeuStim™ to the market in the coming year, aiming to enhance rehabilitation outcomes for patients with neurological conditions.
Good Shepherd Rehabilitation, a clinical research partner of Neuvotion, recognises the potential of NeuStim™ to improve recovery in stroke and spinal cord injury rehabilitation.
The organisation acknowledges the technology as a significant step forward in neuromodulation and neurorehabilitation.
